KRAS and non-small cell lung carcinoma: The first clinical breakthrough was achieved with sotorasib (AMG 510), an irreversible covalent inhibitor targeting KRAS G12C, which received FDA approval for advanced non–small cell lung cancer (NSCLC) [47,48].